• Immunization:
    • Adult: IM 1mL *2 doses 6-12 months apart
    • >1 year: IM 0.5ml *2 doses 6-12 months apart
    • At risk population:
      • Chronic liver disease
      • HIV infection
      • Men who have sex with men
      • Injection or non-injection drug use
      • Homeless patients
      • Working with hepatitis A virus
      • Travel in countries with high or intermediate endemic HAV infection
      • Pregnancy if at risk for infection or severe outcome from infection during pregnancy
      • Setting for exposure, including healthcare settings targeting services to injection or non-injection drugs users or group homes, nonresidential day care facilities for developmentally disabled persons
  • Post exposure prophylaxis:
    • Adult: IM 1ml *1
    • >1 year: IM 0.5ml *1
  • Injection:
    • 1440 EU/mL
    • 720 EU/0.5mL
  • Do not dilute
  • > 2 years: Administer in deltoid region
  • <2 years: Administer in anterolateral area of the thigh

Inactivated vaccine

It induces antibody formation

  • Injection site reaction
  • Irritability
  • Anorexia
  • Fatigue
  • Headache
  • Fever
  • Malaise
  • Nausea
  • Hypersensitivity to class/components
  • Hypersensitivity to neomycin
  • Belimumab

                          Drug Status

Availability Prescription only
Pregnancy Category C unless at risk
Breastfeeding Can be used
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Avaxim 160 U/0.5mL Pre-Filled Syringe 1’s Sanofi Pasteur Ressourcethica Kenya
Avaxim Pediatric 80 U/0.5mL Pre-Filled Syringe 1’s Sanofi Pasteur Ressourcethica Kenya
Havrix Adult 1440 EU/mL Injection 1’s GSK Ltd GSK Ltd
Havrix Junior 720 EU/0.5mL Injection 1’s GSK Ltd GSK Ltd